HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has secured approval from Japan’s Ministry of Health, Labor, and Welfare for its XTRAC Momentum™ 1.0 device. This advanced excimer laser, initially launched in the U.S. in early 2022, is now set for immediate commercial rollout in Japan through JMEC Co., Ltd., STRATA’s strategic partner and distributor.
STRATA’s excimer technology is already in use at over 300 hospitals and private dermatology clinics across Japan. The XTRAC Momentum™ 1.0 represents a significant leap in excimer laser technology, offering higher power and faster repetition rates compared to previous models. It also features a new user interface and a slim design aimed at enhancing the treatment experience.
“With this regulatory approval, we are now able to offer the Momentum™ device — our most advanced excimer laser — into the Japanese dermatology market. Working with JMEC, we look forward to introducing doctors and patients to the benefits of Momentum™ for the treatment of various dermatology conditions, such as psoriasis, eczema, and vitiligo,” said STRATA’s President and CEO Dr. Dolev Rafaeli.
The XTRAC® excimer laser technology allows for precise delivery of targeted UVB light therapy to specific areas of the skin. This treatment is suitable for both adult and pediatric patients suffering from inflammatory skin conditions like psoriasis, atopic dermatitis, and vitiligo. The new Momentum™ 1.0 device is expected to improve the effectiveness and efficiency of these treatments in Japan.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.